ABSTRACT Current chemotherapeutic regimens achieve CR in a large percentage of patients with AML. However, relapse after CR remains a significant problem. The presence of leukemic cells at

levels too low to be detected by conventional microscopy, termed minimal residual disease (MRD), has been associated with an increased risk of relapse and shortened survival. Detection of

MRD requires the use of highly sensitive ancillary techniques. Multi-color flow cytometric immunophenotyping is a sensitive method for quick and accurate detection of MRD. Use of this method

in patient management may result in lower rates of relapse and improved survival, and is an effective means of assessing novel therapeutic agents. This method can be used in the vast

its advantages and limitations, and discuss the methods employed at our institution. We also review several possible areas of future investigation. Access through your institution Buy or

subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online

access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS

REPRODUCIBLE MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN ACUTE MYELOID LEUKEMIA Article Open access 18 July 2022 PRE-EMPTIVE DETECTION AND EVOLUTION OF

RELAPSE IN ACUTE MYELOID LEUKEMIA BY FLOW CYTOMETRIC MEASURABLE RESIDUAL DISEASE SURVEILLANCE Article Open access 18 June 2024 THE KAPPA/LAMBDA RATIO OF SURFACE IMMUNOGLOBULIN LIGHT CHAIN AS

A VALUABLE PARAMETER FOR MRD ASSESSMENT IN CLL WITH ATYPICAL IMMUNOPHENOTYPE Article Open access 11 June 2024 REFERENCES * Estey EH . Acute myeloid leukemia: 2013 update on

risk-stratification and management. _Am J Hematol_ 2013; 88: 318–327. Article  CAS  Google Scholar  * Ravandi F . Relapsed acute myeloid leukemia: why is there no standard of care? _Best

Pract Res Clin Haematol_ 2013; 26: 253–259. Article  Google Scholar  * Bachas C, Schuurhuis GJ, Assaraf YG, Kwidama ZJ, Kelder A, Wouters F _et al_. The role of minor subpopulations within

the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. _Leukemia_ 2012; 26: 1313–1320. Article  CAS  Google Scholar  * San Miguel JF, Martínez A,

Macedo A, Vidriales MB, López-Berges C, González M _et al_. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia

patients. _Blood_ 1997; 90: 2465–2470. CAS  PubMed  Google Scholar  * Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK _et al_. Diagnosis and management of acute myeloid

leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. _Blood_ 2010; 15: 453–474. Article  Google Scholar  * Grossmann V, Schnittger

S, Kohlmann A, Eder C, Roller A, Dicker F _et al_. A novel hierarchical prognostic model of AML solely based on molecular mutations. _Blood_ 2012; 120: 2963–2972. Article  CAS  Google

Scholar  * Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F _et al_. Prognostic and therapeutic implications of minimal residual disease detection in acute

myeloid leukemia. _Blood_ 2012; 119: 332–341. Article  CAS  Google Scholar  * Hourigan CS, Karp JE . Minimal residual disease in acute myeloid leukaemia. _Nat Rev Clin Oncol_ 2013; 10:

460–471. Article  CAS  Google Scholar  * Jorgensen JL, Chen SS . Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications. _Clin Lymphoma Myeloma Leuk_

2011; 11: S49–S53. Article  Google Scholar  * Harris R . Leukaemia antigens and immunity in man. _Nature_ 1973; 241: 95–100. Article  CAS  Google Scholar  * Baker MA, Ramachandar K, Taub RN

. Specificity of heteroantisera to human acute leukemia-associated antigens. _J Clin Invest_ 1974; 54: 1273–1278. Article  CAS  Google Scholar  * Greaves MF . Proceedings: surface antigens

of leukaemic cells. _Br J Cancer_ 1975; 32: 280–281. Article  CAS  Google Scholar  * Terstappen LW, Safford M, Könemann S, Loken MR, Zurlutter K, Büchner T _et al_. Flow cytometric

characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. _Leukemia_ 1992; 6: 70–80. CAS  PubMed  Google Scholar  * Drach J, Drach D, Glassl H, Gattringer

C, Huber H . Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. _Cytometry_ 1992; 13: 893–901. Article  CAS  Google

Scholar  * Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW _et al_. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. _Blood_ 1993; 81:

3083–3090. CAS  PubMed  Google Scholar  * Macedo A, Orfão A, Vidriales MB, López-Berges MC, Valverde B, González M _et al_. Characterization of aberrant phenotypes in acute myeloblastic

leukemia. _Ann Hematol_ 1995; 70: 189–194. Article  CAS  Google Scholar  * San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C _et al_. Early

immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

_Blood_ 2001; 98: 1746–1751. Article  CAS  Google Scholar  * Al-Mawali A, Gillis D, Hissaria P, Lewis I . Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute

myeloid leukemia using specific five-color multiparameter flow cytometry. _Am J Clin Pathol_ 2008; 129: 934–945. Article  Google Scholar  * Al-Mawali A, Gillis D, Lewis I . The role of

multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. _Am J Clin Pathol_ 2009; 131: 16–26. Article  Google Scholar  * Baer MR, Stewart CC, Dodge

RK, Leget G, Sulé N, Mrózek K _et al_. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group

B Study 8361). _Blood_ 2001; 97: 3574–3580. Article  CAS  Google Scholar  * Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U _et al_. Immunophenotypic

differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. _Cytometry B Clin Cytom_ 2005; 63: 1–9. Article  Google Scholar  * Payne KJ, Crooks GM . Human

hematopoietic lineage commitment. _Immunol Rev_ 2002; 187: 48–64. Article  Google Scholar  * Wood B . Multicolor immunophenotyping: human immune system hematopoiesis. _Methods Cell Biol_

2004; 75: 559–576. Article  Google Scholar  * Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO _et al_. Immunophenotypic evidence of leukemia after induction therapy

predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. _Blood_ 2003; 101: 3398–3406. Article  CAS  Google Scholar  *

Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA _et al_. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with _de novo_

acute myeloid leukemia: a report from Children's Oncology Group. _Blood_ 2012; 120: 1581–1588. Article  Google Scholar  * Paietta E . Minimal residual disease in acute myeloid leukemia:

coming of age. _Hematology Am Soc Hematol Educ Program_ 2012; 2012: 35–42. PubMed  Google Scholar  * Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C _et al_. Level of

minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. _Blood_ 2000; 96: 3948–3952. CAS  PubMed  Google Scholar  * Langebrake C, Creutzig U, Dworzak

M, Hrusak O, Mejstrikova E, Griesinger F _et al_. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. _J Clin

Oncol_ 2006; 24: 3686–3692. Article  Google Scholar  * Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T . Prognostic impact of early response to induction therapy as

assessed by multiparameter flow cytometry in acute myeloid leukemia. _Haematologica_ 2004; 89: 528–540. PubMed  Google Scholar  * Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S,

Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute

myeloid leukemia. _Blood_ 2004; 104: 3078–3085. Article  CAS  Google Scholar  * Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J _et al_. Minimal residual disease-directed therapy

for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. _Lancet Oncol_ 2010; 11: 543–552. Article  CAS  Google Scholar  * Inaba H, Coustan-Smith E, Cao X, Pounds SB,

Shurtleff SA, Wang KY _et al_. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. _J Clin Oncol_ 2012; 30: 3625–3632. Article  Google

Scholar  * Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM _et al_. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell

transplantation for AML in first and second complete remission. _Blood_ 2013; 10: 1813–1821. Article  Google Scholar  * Hokland P, Ommen HB . Towards individualized follow-up in adult acute

myeloid leukemia in remission. _Blood_ 2011; 117: 2577–2584. Article  CAS  Google Scholar  * Coustan-Smith E, Campana D . Should evaluation for minimal residual disease be routine in acute

myeloid leukemia? _Curr Opin Hematol_ 2013; 20: 86–92. Article  Google Scholar  * Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R _et al_. Prospective minimal residual

disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. _J Clin Oncol_ 2009; 27: 3650–3658. Article  CAS  Google Scholar  *

Grimwade D, Vyas P, Freeman S . Assessment of minimal residual disease in acute myeloid leukemia. _Curr Opin Oncol_ 2010; 22: 656–663. Article  Google Scholar  * Al-Mawali A, Gillis D, Lewis

I . The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies

patients with high risk of relapse. _Cytometry B Clin Cytom_ 2009; 76: 91–101. Article  Google Scholar  * Feller N, van der Velden VH, Brooimans RA, Boeckx N, Preijers F, Kelder A _et al_.

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. _Blood Cancer J_ 2013; advance online

publication 2 August 2013, doi:10.1038/bcj.2013.27. * Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W _et al_. Immunophenotyping of acute leukemia and lymphoproliferative

disorders: a consensus proposal of the European LeukemiaNet Work Package 10. _Leukemia_ 2011; 25: 567–574. Article  Google Scholar  * Freeman SD, Jovanovic JV, Grimwade D . Development of

minimal residual disease-directed therapy in acute myeloid leukemia. _Semin Oncol_ 2008; 35: 388–400. Article  CAS  Google Scholar  * Pedreira CE, Costa ES, Arroyo ME, Almeida J, Orfao A . A

multidimensional classification approach for the automated analysis of flow cytometry data. _IEEE Trans Biomed Eng_ 2008; 55: 1155–1162. Article  Google Scholar  * Fišer K, Sieger T,

Schumich A, Wood B, Irving J, Mejstříková E _et al_. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. _Cytometry A_ 2012;

81: 25–34. Article  Google Scholar  * Aghaeepour N, Finak G, Hoos H, Mosmann TR . FlowCAP Consortium, DREAM Consortium Critical assessment of automated flow cytometry data analysis

techniques. _Nat Methods_ 2013; 10: 228–238. Article  CAS  Google Scholar  * Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive

hematopoietic cell. _Nat Med_ 1997; 3: 730–737. Article  CAS  Google Scholar  * Hope KJ, Jin L, Dick JE . Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes

that differ in self-renewal capacity. _Nat Immunol_ 2004; 5: 738–743. Article  CAS  Google Scholar  * van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B _et al_. The

novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. _Blood_ 2007; 110: 2659–2666. Article  CAS  Google Scholar  * Majeti R, Chao MP,

Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr. _et al_. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. _Cell_ 2009; 138:

286–299. Article  CAS  Google Scholar  * Majeti R . Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. _Oncogene_ 2011; 30: 1009–1019. Article  CAS  Google

Scholar  * Hokland P, Ommen HB, Nyvold CG, Roug AS . Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission–methodologies in relation to their clinical

situation. _Br J Haematol_ 2012; 158: 569–580. Article  Google Scholar  * Jawad M, Yu N, Seedhouse C, Tandon K, Russell NH, Pallis M . Targeting of CD34+CD38− cells using Gemtuzumab

ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute myeloid leukaemia. _BMC Cancer_ 2012; 12: 431. Article  CAS  Google Scholar  * Cilloni D, Gottardi E, De Micheli D,

Serra A, Volpe G, Messa F _et al_. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia

patients. _Leukemia_ 2002; 16: 2115–2121. Article  CAS  Google Scholar  * Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C _et al_. High WT1 expression after induction

therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. _J Clin Oncol_ 2006; 24: 1507–1515. Article  CAS  Google Scholar  * Cilloni D, Messa F, Arruga F,

Defilippi I, Gottardi E, Fava M _et al_. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after

chemotherapy. _Haematologica_ 2008; 93: 921–924. Article  Google Scholar  * Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A _et al_. Quantitative assessment of

WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. _Eur J Haematol_ 2009; 82: 61–68. Article 

CAS  Google Scholar  * Válková V, Polák J, Marková M, Vítek A, Hájková H, Sálek C _et al_. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem

cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. _Clin Transplant_ 2013; 27: E21–E29. Article  Google Scholar  * Zhao

XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY _et al_. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting

specificity. _Ann Hematol_ 2013; 92: 1111–1119. Article  CAS  Google Scholar  * Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV _et al_. Real-time quantitative polymerase

chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. _J Clin Oncol_ 2009;

27: 5195–5201. Article  CAS  Google Scholar  * Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P _et al_. Cytogenetic and molecular diagnostic characterization

combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. _Blood_ 2010; 116: 2295–2303. Article  CAS 

Google Scholar  * Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P _et al_. Prospective evaluation of gene mutations and minimal residual disease in patients with core

binding factor acute myeloid leukemia. _Blood_ 2013; 121: 2213–2223. Article  CAS  Google Scholar  * Kaplan D, Husel W, Meyerson H . Immunophenotypic analysis with enhanced sensitivity of

detection by enzymatic amplification staining. _Clin Lab Med_ 2001; 21: 763–778. CAS  PubMed  Google Scholar  * Mattison RJ, Luger SM, Lazarus HM . New strategies for the evaluation of the

nadir bone marrow following induction in acute myeloid leukemia. _Curr Opin Hematol_ 2013; 20: 93–99. Article  CAS  Google Scholar  * Liso V, Albano F, Pastore D, Carluccio P, Mele G,

Lamacchia M _et al_. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in _de novo_ adult acute myeloid leukemia. _Haematologica_ 2000; 85: 1285–1290. CAS 

PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA J M

Jaso, S A Wang, J L Jorgensen & P Lin Authors * J M Jaso View author publications You can also search for this author inPubMed Google Scholar * S A Wang View author publications You can

also search for this author inPubMed Google Scholar * J L Jorgensen View author publications You can also search for this author inPubMed Google Scholar * P Lin View author publications You

can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to P Lin. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflicts of interest.

RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jaso, J., Wang, S., Jorgensen, J. _et al._ Multi-color flow cytometric immunophenotyping for detection of

minimal residual disease in AML: past, present and future. _Bone Marrow Transplant_ 49, 1129–1138 (2014). https://doi.org/10.1038/bmt.2014.99 Download citation * Received: 04 December 2013

* Revised: 15 March 2014 * Accepted: 21 March 2014 * Published: 19 May 2014 * Issue Date: September 2014 * DOI: https://doi.org/10.1038/bmt.2014.99 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative